The Latest Breaking News from TGTX

A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry’s bright outlook, biotech stocks MannKind (MNKD), Illumina (ILMN), and TG Therapeutics (TGTX) could be ideal watchlist additions for potential growth. Read…

Sales of a new multiple sclerosis drug from TG crushed analysts' expectations, but TGTX stock tumbled on lackluster 2024 guidance.

TG Therapeutics' new MS drug, Briumvi, experienced a "solid jump" in March sales, according to a report. TGTX stock broke out Tuesday.

Growth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment.

TG Therapeutics Inc's (NASDAQ:TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) HC Wainwright has slashed the price target from $68 to $19, with the Buy rating unchanged.…

The FDA has extended the review period of TG Therapeutics Inc's (NASDAQ:TGTX) biologics license application and supplemental New Drug Application for ublituximab in combination with Ukoniq (umbralisib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The Prescription Drug User Fee Act (PDUFA) goal date is postponed to June 25. The FDA notified…

TG Therapeutics Inc's (NASDAQ: TGTX) CEO Michael Weiss said that the FDA has 

Within the last quarter, TG Therapeutics (NASDAQ:TGTX) has observed the following analyst ratings: